ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Egalet Corporation (EGLT) Report Updated: Mar 25, 2017 | Print This Page

Get more stock ratings by Louis Navellier

Egalet Corporation (EGLT)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Pharmaceuticals
Competitors: HSKA,CPIX,ASMB,CORT

Stock Analysis

Rating: Monthly View

A
B
C
D
F
March April May June July August September October November December January February

Rating: Weekly View

This Week: F down no change
Last Week: F same downgrade
Two Weeks Ago: D up upgrade
service keys

Egalet Corporation© quotemedia

Company Profile

Egalet Corporation, a specialty pharmaceutical company, engages in developing, manufacturing, and commercializing medicines for patients with acute and chronic pain. It has licensed two approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; and OXAYDO, an immediate-release oxycodone product formulated to deter abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate. The company also develops a pipeline of clinical-stage, opioid-based product candidates that are specifically designed to deter abuse by physical and chemical manipulation using its proprietary Guardian Technology. Its product candidates include Egalet-001 and Egalet-002 that are abuse-deterrent, extended-release, oral formulations for the treatment of moderate and severe pain. The company has a collaboration and license agreement with Shionogi Limited to develop, manufacture, and commercialize abuse-deterrent hydrocodone-based product candidates using its technology. Egalet Corporation was founded in 2010 and is headquartered Wayne, Pennsylvania.